{
    "ticker": "NLSP",
    "name": "NLS Pharmaceutics AG",
    "description": "NLS Pharmaceutics AG is a biopharmaceutical company focused on the development of innovative treatments for central nervous system (CNS) disorders. Founded in 2017 and headquartered in Zurich, Switzerland, NLS is dedicated to addressing unmet medical needs in the fields of sleep disorders and neuropsychiatric conditions. The company's lead product candidate, NLS-1, is designed to treat narcolepsy, a chronic sleep disorder characterized by excessive daytime sleepiness and sudden sleep attacks. NLS Pharmaceutics employs a unique formulation technology that allows for the sustained release of active pharmaceutical ingredients, enhancing therapeutic outcomes and patient compliance. The company is committed to advancing its pipeline through rigorous clinical trials and collaborations with leading research institutions. NLS Pharmaceutics aims to improve the quality of life for patients suffering from debilitating disorders by providing effective and safe treatment options. With a strong scientific foundation and a passion for innovation, NLS is poised to make significant contributions to the field of CNS therapeutics.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Zurich, Switzerland",
    "founded": "2017",
    "website": "https://www.nlspharma.com",
    "ceo": "Dr. Alexander K. D. G. W. R. K. M\u00fcller",
    "social_media": {
        "twitter": "https://twitter.com/NLSPharmaceutics",
        "linkedin": "https://www.linkedin.com/company/nls-pharmaceutics/"
    },
    "investor_relations": "https://www.nlspharma.com/investors",
    "key_executives": [
        {
            "name": "Dr. Alexander K. D. G. W. R. K. M\u00fcller",
            "position": "CEO"
        },
        {
            "name": "Dr. Stefan K. St\u00e4uble",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "CNS Therapeutics",
            "products": [
                "NLS-1"
            ]
        }
    ],
    "seo": {
        "meta_title": "NLS Pharmaceutics AG | Innovative CNS Treatments",
        "meta_description": "Explore NLS Pharmaceutics AG, a biopharmaceutical company dedicated to developing innovative treatments for CNS disorders, focusing on narcolepsy and sleep disorders.",
        "keywords": [
            "NLS Pharmaceutics",
            "CNS Disorders",
            "Narcolepsy",
            "Biopharmaceuticals",
            "Sleep Disorders"
        ]
    },
    "faq": [
        {
            "question": "What does NLS Pharmaceutics focus on?",
            "answer": "NLS Pharmaceutics focuses on developing innovative treatments for central nervous system disorders, particularly narcolepsy."
        },
        {
            "question": "Who is the CEO of NLS Pharmaceutics?",
            "answer": "Dr. Alexander K. D. G. W. R. K. M\u00fcller is the CEO of NLS Pharmaceutics AG."
        },
        {
            "question": "Where is NLS Pharmaceutics headquartered?",
            "answer": "NLS Pharmaceutics is headquartered in Zurich, Switzerland."
        },
        {
            "question": "What is NLS-1?",
            "answer": "NLS-1 is the lead product candidate of NLS Pharmaceutics, designed to treat narcolepsy."
        },
        {
            "question": "When was NLS Pharmaceutics founded?",
            "answer": "NLS Pharmaceutics was founded in 2017."
        }
    ],
    "competitors": [
        "AVDL",
        "NVCR",
        "SAGE"
    ],
    "related_stocks": [
        "VRTX",
        "BIIB",
        "REGN",
        "AMGN"
    ]
}